For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Integra Lifesciences Holdings Corp (NASDAQ: IART) closed at $13.12 down -0.98% from its previous closing price of $13.25. In other words, the price has decreased by -$0.98 from its previous closing price. On the day, 0.82 million shares were traded. IART stock price reached its highest trading level at $13.43 during the session, while it also had its lowest trading level at $13.09.
Ratios:
For a deeper understanding of Integra Lifesciences Holdings Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.80 and its Current Ratio is at 3.14. In the meantime, Its Debt-to-Equity ratio is 1.93 whereas as Long-Term Debt/Eq ratio is at 1.88.
On December 02, 2024, Morgan Stanley started tracking the stock assigning a Underweight rating and target price of $20.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 05 ’25 when GRAVES JEFFREY A bought 9,000 shares for $11.35 per share. The transaction valued at 102,150 led to the insider holds 41,086 shares of the business.
Schwartz Eric sold 4,070 shares of IART for $100,102 on Dec 03 ’24. The EVP, Chief Legal Officer & Sec now owns 59,511 shares after completing the transaction at $24.59 per share. On Dec 03 ’24, another insider, Schwartz Eric, who serves as the Officer of the company, bought 4,070 shares for $24.59 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IART now has a Market Capitalization of 1022189568 and an Enterprise Value of 2761789440. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.62 while its Price-to-Book (P/B) ratio in mrq is 0.98. Its current Enterprise Value per Revenue stands at 1.681 whereas that against EBITDA is 8.663.
Stock Price History:
The Beta on a monthly basis for IART is 1.05, which has changed by -0.46623272 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, IART has reached a high of $27.13, while it has fallen to a 52-week low of $10.87. The 50-Day Moving Average of the stock is -3.05%, while the 200-Day Moving Average is calculated to be -14.71%.
Shares Statistics:
For the past three months, IART has traded an average of 1.16M shares per day and 945500 over the past ten days. A total of 77.83M shares are outstanding, with a floating share count of 65.88M. Insiders hold about 15.42% of the company’s shares, while institutions hold 93.06% stake in the company. Shares short for IART as of 1763078400 were 6529500 with a Short Ratio of 5.63, compared to 1760486400 on 6689405. Therefore, it implies a Short% of Shares Outstanding of 6529500 and a Short% of Float of 13.639999999999999.
Earnings Estimates
The company has 9.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.49, with high estimates of $0.54 and low estimates of $0.43.
Analysts are recommending an EPS of between $2.22 and $2.17 for the fiscal current year, implying an average EPS of $2.2. EPS for the following year is $2.37, with 12.0 analysts recommending between $2.55 and $2.27.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $432.89M this quarter.It ranges from a high estimate of $459.3M to a low estimate of $426.08M. As of. The current estimate, Integra Lifesciences Holdings Corp’s year-ago sales were $442.64MFor the next quarter, 10 analysts are estimating revenue of $392.15M. There is a high estimate of $398.4M for the next quarter, whereas the lowest estimate is $382.01M.
A total of 11 analysts have provided revenue estimates for IART’s current fiscal year. The highest revenue estimate was $1.67B, while the lowest revenue estimate was $1.63B, resulting in an average revenue estimate of $1.63B. In the same quarter a year ago, actual revenue was $1.61BBased on 11 analysts’ estimates, the company’s revenue will be $1.68B in the next fiscal year. The high estimate is $1.75B and the low estimate is $1.65B.
